March 2017 Innovations Grand Rounds
Wednesday, March 15, 7:00 - 8:00AM
Toland Hall, 533 Parnassus, Room U-142 (map)
Mauro Ferrari, PhD
Ernest Cockrell Jr. Presidential Distinguished Chair
President & CEO, Houston Methodist Research Institute
Director, Institute for Academic Medicine
Abstract: Wait, not as in “post-mortem”…. Rather as in “post-genomics”…. As in: “Let’s use the knowledge gained in these last 20 years or so of research and development in nanomedicine and build the next generation of advances, where needed”. This is the focus of the talk, with an obvious bias toward the lines of investigation and clinical translation that we have been engaging in – simply because though they are probably not the smartest things around, these are still the ones we know best! So I will talk about a 25-year progression ( = string of failures, mostly) from photolithography-based silicon particles with drug reservoirs (1992) and the beginning of nanofluidics (1994ish) to multi-stage injectable drug delivery systems coupling micro- and nano-platforms (2008) with nanoporous silicon; transport oncophysics (2011) with its applications to immunotherapy (2015), to end with a new beginning: injectable nano-particle generators (iNPG), which in combination with polymeric doxorubicin (pDox) are actually able to completely cure metastatic forms of triple negative breast cancer in about 40% of the cases in preclinical models. It was time, no? Next challenge – move to clinic. Coming up.
About the speaker: Mauro Ferrari, PhD, is the Ernest Cockrell Jr. Presidential Distinguished Chair, President, and CEO of Houston Methodist Research Institute. He also serves as Director of the Institute for Academic Medicine, Executive Vice President of Houston Methodist Hospital System, and Senior Associate Dean and Professor of Medicine at Weill Cornell Medical College in New York. Before joining Houston Methodist in 2010, Ferrari founded and chaired the Department of Nanomedicine and Biomedical Engineering at University of Texas Health Science Center in Houston – the first department of nanomedicine at a medical school.
A pioneer in the field of nanomedicine, Ferrari blends his expertise in fluid mechanics and nanotechnology to develop new methods of cancer drug delivery, cell transplantation, disease diagnosis, and personalized medicine. He has been recognized for his contributions to the field through the Founders Award – Controlled Release Society, the Wallace H. Coulter Award for Biomedical Innovation and Entrepreneurship, The ETH Zurich Stodola Medal, Blaise Pascal Medal in Biomedical Engineering – European Academy of Sciences, and the Shannon Director’s Award of the National Institutes of Health.
Dr. Ferrari studied Mathematics at the Universita' di Padova in Italy before earning his Ph.D. in Mechanical Engineering from UC Berkeley. He has contributed to over 350 publications, including seven books, and holds 30 issued patents in the U.S. and Europe.